News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
235,539 Results
Type
Article (19028)
Company Profile (161)
Press Release (216347)
Multimedia
Podcasts (50)
Webinars (6)
Section
Business (62156)
Career Advice (198)
Deals (9076)
Drug Delivery (64)
Drug Development (34334)
Employer Resources (34)
FDA (6891)
Job Trends (6307)
News (113095)
Policy (11466)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (1595)
Academic (1)
Accelerated approval (20)
Adcomms (14)
Allergies (79)
Alliances (17939)
ALS (78)
Alzheimer's disease (745)
Antibody-drug conjugate (ADC) (144)
Approvals (7180)
Artificial intelligence (277)
Autoimmune disease (94)
Automation (18)
Bankruptcy (55)
Best Places to Work (6017)
BIOSECURE Act (7)
Biosimilars (137)
Biotechnology (112)
Bladder cancer (95)
Brain cancer (25)
Breast cancer (333)
Cancer (2510)
Cardiovascular disease (259)
Career advice (184)
Career pathing (7)
CAR-T (154)
CDC (17)
Celiac Disease (1)
Cell therapy (426)
Cervical cancer (13)
Clinical research (30569)
Collaboration (981)
Company closure (1)
Compensation (407)
Complete response letters (23)
COVID-19 (1167)
CRISPR (72)
C-suite (471)
Cystic fibrosis (94)
Data (3701)
Decentralized trials (1)
Denatured (22)
Depression (69)
Diabetes (280)
Diagnostics (2368)
Digital health (24)
Diversity (8)
Diversity, equity & inclusion (13)
Drug discovery (152)
Drug pricing (119)
Drug shortages (19)
Duchenne muscular dystrophy (138)
Earnings (20473)
Editorial (26)
Employer branding (2)
Employer resources (35)
Events (35694)
Executive appointments (494)
FDA (8635)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (12)
Funding (667)
Gene editing (147)
Generative AI (28)
Gene therapy (370)
GLP-1 (554)
Government (1727)
Grass and pollen (5)
Guidances (171)
Healthcare (7688)
HIV (44)
Huntington's disease (25)
IgA nephropathy (54)
Immunology and inflammation (102)
Immuno-oncology (34)
Indications (72)
Infectious disease (1306)
Inflammatory bowel disease (131)
Inflation Reduction Act (7)
Influenza (59)
Intellectual property (85)
Interviews (14)
IPO (4381)
IRA (28)
Job creations (725)
Job search strategy (167)
JPM (33)
Kidney cancer (11)
Labor market (18)
Layoffs (145)
Leadership (8)
Legal (1812)
Liver cancer (41)
Longevity (8)
Lung cancer (354)
Lymphoma (245)
Machine learning (21)
Management (11)
Manufacturing (406)
MASH (95)
Medical device (2681)
Medtech (2695)
Mergers & acquisitions (5130)
Metabolic disorders (714)
Multiple sclerosis (80)
NASH (12)
Neurodegenerative disease (156)
Neuropsychiatric disorders (40)
Neuroscience (1380)
NextGen: Class of 2026 (2146)
Non-profit (1717)
Now hiring (16)
Obesity (341)
Opinion (101)
Ovarian cancer (87)
Pain (115)
Pancreatic cancer (97)
Parkinson's disease (134)
Partnered (14)
Patents (158)
Patient recruitment (245)
Peanut (24)
People (23296)
Pharmaceutical (33)
Pharmacy benefit managers (15)
Phase 1 (8544)
Phase 2 (12367)
Phase 3 (11942)
Pipeline (2799)
Policy (154)
Postmarket research (1437)
Preclinical (3379)
Press Release (17)
Prostate cancer (127)
Psychedelics (16)
Radiopharmaceuticals (163)
Rare diseases (519)
Real estate (1571)
Recruiting (12)
Regulatory (10404)
Reports (13)
Research institute (1407)
Resumes & cover letters (17)
Rett syndrome (24)
RNA editing (11)
RSV (35)
Schizophrenia (80)
Series A (129)
Series B (103)
Sickle cell disease (76)
Special edition (8)
Spinal muscular atrophy (91)
Sponsored (18)
Startups (1384)
Stomach cancer (7)
Supply chain (49)
Tariffs (52)
The Weekly (27)
Vaccines (418)
Venture capital (44)
Weight loss (221)
Women's health (43)
Worklife (1)
Date
Last 7 days (270)
Last 30 days (1031)
Last 365 days (14032)
2026 (1912)
2025 (14187)
2024 (15500)
2023 (16819)
2022 (21018)
2021 (21805)
2020 (19915)
2019 (17148)
2018 (12854)
2017 (12087)
2016 (11235)
2015 (12105)
2014 (8470)
2013 (6956)
2012 (7062)
2011 (7021)
2010 (5685)
Location
Africa (245)
Alabama (30)
Alaska (1)
Arizona (62)
Arkansas (3)
Asia (15916)
Australia (2175)
California (5066)
Canada (1170)
China (588)
Colorado (165)
Connecticut (252)
Delaware (233)
Europe (35753)
Florida (707)
Georgia (138)
Hawaii (1)
Idaho (15)
Illinois (407)
India (39)
Indiana (336)
Iowa (6)
Japan (325)
Kansas (55)
Kentucky (9)
Louisiana (11)
Maine (28)
Maryland (510)
Massachusetts (4208)
Michigan (48)
Minnesota (131)
Mississippi (1)
Missouri (65)
Montana (9)
Nebraska (4)
Nevada (31)
New Hampshire (14)
New Jersey (1758)
New Mexico (11)
New York (1433)
North Carolina (664)
North Dakota (6)
Northern California (2669)
Ohio (124)
Oklahoma (5)
Oregon (22)
Pennsylvania (993)
Puerto Rico (4)
Rhode Island (17)
South America (301)
South Carolina (8)
Southern California (1840)
Tennessee (47)
Texas (605)
United States (18344)
Utah (157)
Vermont (1)
Virginia (135)
Washington D.C. (44)
Washington State (434)
Wisconsin (51)
235,539 Results for "homology medicines".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Homology Medicines Declares Distribution to Common Stockholders
Homology Medicines, Inc. announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right for each outstanding share of Homology common stock held by such stockholder as of such record date.
March 18, 2024
·
6 min read
Business
Homology Medicines Reports Third Quarter 2023 Financial Results
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today third quarter 2023 financial results and highlighted recent updates.
November 14, 2023
·
9 min read
Deals
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
Q32 Bio Inc. (NASDAQ: QTTB) (“Q32 Bio”), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced the completion of its previously announced merger with Homology Medicines, Inc. (“Homology”).
March 25, 2024
·
9 min read
Deals
Q32 Bio and Homology Medicines Announce Merger Agreement
Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc., announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
November 16, 2023
·
17 min read
Genetown
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
Homology Medicines, Inc. announced that it received notification from The Nasdaq Stock Market LLC on December 29, 2023 indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Select Market ).
January 3, 2024
·
11 min read
Business
Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today second quarter 2023 financial results and highlighted recent updates.
August 14, 2023
·
11 min read
Business
Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights
Homology Medicines, Inc., a genetic medicines company, announced financial results for the first quarter ended March 31, 2023, and highlighted recent accomplishments.
May 11, 2023
·
11 min read
Genetown
Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has completed a review of its business, and the Board of Directors has approved a plan to evaluate strategic alternatives to maximize shareholder value.
July 27, 2023
·
6 min read
Business
Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Julie Jordan, M.D., has been promoted to Chief Medical Officer.
March 9, 2023
·
7 min read
Genetown
Homology Medicines to Participate at Upcoming Conferences - October 06, 2022
Homology Medicines, Inc., a clinical-stage genetic medicines company, announced participation at the following conferences.
October 6, 2022
·
2 min read
1 of 23,554
Next
